Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
05/19/20, 11:03 AM
Location
new havenMoney raised
$145 million
Round Type
series b
Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the completion of a $145 million Series B financing led by Pivotal bioVenture Partners. New investors participating in the financing include Viking Global Investors, TPG’s The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management LLC, Solasta Ventures, Fairview Capital, and Mitsui & Co. Global Investment Inc. The Company’s existing investors, 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations, also participated in the financing.
Company Info
Location
new haven, kentucky, united states
Additional Info
We are making science’s hardest obstacles our highest priority. Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 complement inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut.
Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward as we strive to develop and deliver the truly transformational.
Read our Community Guidelines here: https://bit.ly/RLYBCGs